INTEGRAGEN |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.65 EUR | -0.76% |
|
-5.80% | -27.29% |
| 2023 | IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | IntegraGen SA Announces Revenue Results for the First Half of 2023 | CI |
| Sales 2019 | 8.28M 8.82M | Sales 2020 | 9M 9.59M | Capitalization | 13.61M 14.5M |
|---|---|---|---|---|---|
| Net income 2019 | - 0 | Net income 2020 | - 0 | EV / Sales 2019 | 0.49 x |
| Net cash position 2019 | 2.52M 2.68M | Net cash position 2020 | 3.11M 3.31M | EV / Sales 2020 | 1.17 x |
| P/E ratio 2019 |
-23
x | P/E ratio 2020 |
-36.6
x | Employees | 57 |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 32.97% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.76% | ||
| 1 week | -5.80% | ||
| Current month | -8.71% | ||
| 1 month | -5.80% | ||
| 3 months | -21.69% | ||
| 6 months | -46.72% | ||
| Current year | -27.29% |
1 week
0.65
0.71
1 month
0.630.86
Current year
0.630.93
1 year
0.631.57
3 years
0.632.04
5 years
0.632.67
10 years
0.639.68
| Managers | Title | Age | Since |
|---|---|---|---|
Bernard Courtieu
CEO | Chief Executive Officer | 60 | 07-09-05 |
Pierre Flamant
DFI | Director of Finance/CFO | - | - |
Francois Degrave
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | - | |
Jean-Pol Detiffe
BRD | Director/Board Member | 51 | - |
| Director/Board Member | - | 18-06-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.65 | -0.76% | 4,768 |
| 24-04-18 | 0.655 | -5.76% | 1,321 |
| 24-04-17 | 0.695 | -0.71% | 520 |
| 24-04-16 | 0.7 | 0.00% | 4,744 |
| 24-04-15 | 0.7 | +1.45% | 596 |
Real-time Euronext Paris, April 19, 2024 at 09:33 am EDT
More quotes
IntegraGen specializes in researching and identifying genetic biomarkers and in developing and marketing molecular diagnostic products and services, primarily in the field of oncology. The group's activity is organized around two sectors:
- supply of genomic research services: high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups;
- sales of diagnostic solutions.
France accounts for 88% of net sales.
Calendar
2024-10-16
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -27.29% | 4.64M | |
| -17.60% | 11.52B | |
| +39.11% | 3.27B | |
| -20.67% | 2.02B | |
| -29.30% | 1.44B | |
| +11.45% | 1.01B | |
| -6.33% | 719M | |
| -30.75% | 418M | |
| -51.02% | 339M | |
| -2.58% | 284M |
- Stock Market
- Equities
- ALINT Stock
